Programmed death-ligand 1
Showing 1 - 25 of >10,000
Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal
Not yet recruiting
- Nasopharyngeal and Hypopharyngeal Carcinoma
- immunohistochemical
-
Sohag, EgyptSohag University Hospital
Oct 23, 2022
Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)
Not yet recruiting
- Acute Lymphoblastic Leukemia in Pediatric
- flow cytometric immunophynotyping
-
Sohag, EgyptSohag University Hospital
Jun 19, 2022
Lung Cancer Trial in Assiut (Observational Study ( Tissue Biopsy ))
Completed
- Lung Cancer
- Observational Study ( Tissue Biopsy )
-
Assiut, EgyptAssiut University
Oct 18, 2021
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Tumor treating fields(EFE-P100)
- Docetaxel injection
-
Shanghai, ChinaShanghai Pulmonary Hospital
Dec 21, 2022
Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)
Recruiting
- Large B-cell Lymphoma
- 89Zr-atezolizumab PET-imaging
-
Groningen, NetherlandsUniversity Medical Center Groningen
Jul 15, 2022
Rectal Cancer Stage, Oesophageal Cancer Trial in Vienna (CRT, SCPRT, CROSS Protocol)
Not yet recruiting
- Rectal Cancer Stage
- Oesophageal Cancer
- CRT
- +3 more
-
Vienna, AustriaMedical University of Vienna
Mar 26, 2022
Tumor-Infiltrating Lymphocytes and Programmed Cell Death -
Recruiting
- Breast Cancer
- +2 more
- Observational Study
-
Lucknow, Uttar Pradesh, IndiaSanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022
PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Monza, ItalyASST-Monza Ospedale San Gerardo
Jun 9, 2022
Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Paclitaxel
- +4 more
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital ( Site 3700)
Jan 31, 2023
Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Atezolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Feb 15, 2022
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab, pemetrexed, platinum
- Osimertinib
-
Peking, ChinaPeking Union Medical College Hospital
Nov 16, 2023
Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma Trial in New York (Nivolumab, Atezolizumab, Radiation &
Terminated
- Metastatic Renal Cell Carcinoma
- Metastatic Urothelial Carcinoma
- Nivolumab
- +3 more
-
New York, New YorkWeill Cornell Medicine - New York Presbyterian Hospital
Aug 26, 2021
NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1
Not yet recruiting
- Non-Small Cell Lung Cancer
- Capsulized Fecal Microbiota Transplant
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Aug 12, 2021
Breast Cancer, Cervix Cancer, Ovarian Cancer Trial in Amsterdam (carbplatin, cyclophophamide, atezolizumab)
Completed
- Breast Cancer
- +3 more
- carbplatin, cyclophophamide, atezolizumab
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek
Oct 18, 2021
Lung Cancer, Non-Small Cell Trial in Worldwide (Pembrolizumab, Dostarlimab, GSK4428859A)
Recruiting
- Lung Cancer, Non-Small Cell
- Pembrolizumab
- +2 more
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- +14 more
Dec 26, 2022
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
Glioblastoma Trial in France (Hypofractionated stereotactic radiation therapy, Durvalumab)
Recruiting
- Glioblastoma
- Hypofractionated stereotactic radiation therapy
- Durvalumab
-
Angers, France
- +9 more
Mar 25, 2022
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sacituzumab Govitecan
- Pembrolizumab
-
Marietta, Georgia
- +2 more
Jan 27, 2023
Germ Cell Tumor Trial in Milano (Durvalumab, Tremelimumab)
Terminated
- Germ Cell Tumor
-
Milano, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
May 12, 2021
Advanced Melanoma Trial in Worldwide (lenvatinib, pembrolizumab)
Active, not recruiting
- Advanced Melanoma
- lenvatinib
- pembrolizumab
-
Chandler, Arizona
- +22 more
Jul 21, 2022